Africa’s limited pharmaceutical industry, high costs of raw materials, and dependence on imported medicines have long hampered citizens’ access to the medicines they need.  The challenges the continent faces are daunting. They include poor supply chain systems, lack of government investment in the pharmaceutical sector, unfavourable manufacturing conditions, limited health workforce, lack of sustainable health […] Continue reading ->
Leading public health experts are calling for urgent action to develop antibiotics for newborn babies, a population that is particularly vulnerable to antibiotic resistance.  Each year, there are an estimated three million cases of neonatal sepsis causing up to 570,000 deaths, many due to a current lack of effective antibiotics, according to a paper published […] Continue reading ->
There should be much harsher penalties, including homicide charges, for those who intentionally falsify medicine and include harmful ingredients, according to Kawaldip Sehmi, CEO of the International Alliance of Patients’ Organisations (IAPO). Sehmi was speaking at an event hosted by Fight the Fakes Alliance in Geneva on Wednesday to highlight the global proliferation of fake […] Continue reading ->
Biotherapeutic products represent a new therapeutic revolution in disease treatment and are by far the fastest-growing segment of the pharmaceutical industry – yet the recent biosimilar guidelines issued by the World Health Organization (WHO) are myopic, inconsistent or vague about some well-established scientific issues Biosimilar products include recombinant proteins and hormones, monoclonal antibodies (mAbs), cytokines, […] Continue reading ->
The United States is considering shifting to intradermal injections of Monkeypox vaccine that could potentially stretch one dose of the approved MVA-BN vaccine, available only in limited quantities, into five doses, said US Food and Drug Administration Commissioner Robert Califf on Thursday. He was speaking at a press briefing minutes after Xavier Becerra, US Secretary […] Continue reading ->
MONTREAL – Ninety countries will benefit from a voluntary licensing agreement announced on Thursday that will enable generic companies to produce a long-acting injectable antiretroviral, cabotegravir (CAB-LA), to protect people from HIV infection. CAB-LA’s manufacturer, UK pharmaceutical company ViiV, has given the license to the Medicines Patent Pool (MPP) for patents in least-developed, low-income, lower-middle-income […] Continue reading ->